FY2024 EPS Estimates for AxoGen Lowered by Cantor Fitzgerald

AxoGen, Inc. (NASDAQ:AXGN) – Investment analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for AxoGen in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now forecasts that the medical equipment provider will post earnings of ($0.58) per share for the year, down from their previous forecast of ($0.28). The consensus estimate for AxoGen’s current full-year earnings is ($0.37) per share. Cantor Fitzgerald also issued estimates for AxoGen’s FY2025 earnings at $0.19 EPS.

Separately, StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th.

AxoGen Stock Performance

Shares of NASDAQ:AXGN opened at $18.14 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The firm has a market cap of $798.34 million, a PE ratio of -56.69 and a beta of 1.01. The firm’s 50 day simple moving average is $15.64 and its 200-day simple moving average is $13.41. AxoGen has a one year low of $5.55 and a one year high of $19.06.

Hedge Funds Weigh In On AxoGen

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in shares of AxoGen by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock valued at $14,170,000 after acquiring an additional 31,612 shares during the last quarter. FMR LLC lifted its position in AxoGen by 743.1% during the third quarter. FMR LLC now owns 178,957 shares of the medical equipment provider’s stock valued at $2,509,000 after purchasing an additional 157,730 shares during the period. Barclays PLC boosted its holdings in AxoGen by 119.3% in the third quarter. Barclays PLC now owns 72,036 shares of the medical equipment provider’s stock valued at $1,010,000 after purchasing an additional 39,182 shares during the last quarter. State Street Corp grew its position in AxoGen by 11.9% during the 3rd quarter. State Street Corp now owns 896,674 shares of the medical equipment provider’s stock worth $12,571,000 after purchasing an additional 95,051 shares during the period. Finally, Principal Financial Group Inc. purchased a new position in AxoGen during the third quarter valued at approximately $207,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.